About Venrock
Venrock is a venture capital firm founded in 1969. It is primarily based out of Palo Alto, United States. As of Jun 2026, Venrock has invested in 47 companies. It primarily invests in Post IPO round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Environment Tech. Most recently it participated in the $***** Series D round of Lycia Therapeutics Overall, Venrock portfolio has seen 20 IPOs and 17 acquisitions including key companies like argenx, Rhythm Pharmaceuticals and RayzeBio. A lot of funds co-invest with Venrock, with names like Boxer Capital sharing a substantial percentage of its portfolio. Venrock has team of 38 people including 16 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Post IPO, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Venrock's List of Top Investments
Venrock has a portfolio of 47 companies. Their most notable investments are in Sojournix and Upstream Bio.Their portfolio spans across United States, Canada, Ireland and 7 more locations. They have invested in Life Sciences, High Tech, Environment Tech and 5 other sectors, across stages such as Post IPO, Series B and 4 more. Here is the list of top investments by Venrock:1. argenx
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llama's and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
Key facts about argenx
- Founded Year: 2008
- Location: Ghent (Belgium)
- Annual Revenue: €1B+ as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $61.9M
- Employee Count: 2,341 as on Sep 30, 2026
- Investors: Venrock, BB Biotech and 21 Others
- Latest Funding Round: Post IPO, Mar 24, 2022, $*****
- Highlight: Public
Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.
Key facts about Rhythm Pharmaceuticals
- Founded Year: 2010
- Location: Boston (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $84M
- Employee Count: 510 as on Sep 30, 2026
- Investors: Venrock, Foresite Capital and 9 Others
- Latest Funding Round: Post IPO, Apr 01, 2024, $*****
- Highlight: Public
3. RayzeBio
Key facts about RayzeBio
- Founded Year: 2019
- Location: San Diego (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $426M
- Employee Count: 288 as on Sep 30, 2026
- Investors: Venrock, Perceptive Advisors and 22 Others
- Latest Funding Round: Series D, Aug 25, 2022, $*****
- Highlight: Acquired
4. Neurocrine
Developer of small molecule therapeutics for endocrine and CNS disorders. The company's product line include elagolix, a gonadotropin-releasing hormone antagonist for endometriosis and uterine leiomyoma, and NBI-98854 a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.
Key facts about Neurocrine
- Founded Year: 1992
- Location: San Diego (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $10M
- Employee Count: 2,476 as on Sep 30, 2026
- Investors: Venrock, BB Biotech and 6 Others
- Latest Funding Round: Post IPO, Aug 05, 2023, $*****
- Highlight: Acquired
Developer of therapeutics to treat acute myeloid leukemia. The company has developed cancer therapeutics using engineered hematopoietic stem cells (eHSC). The company's lead candidate includes VOR33 which targets CD33 protein in cancer patients to treat acute myeloid leukemia (AML).
Key facts about Vor Biopharma
- Founded Year: 2019
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 131 as on Sep 30, 2026
- Investors: HTIF, Venrock and 10 Others
- Latest Funding Round: Post IPO, Dec 15, 2025, $*****
- Highlight: Public
Venrock's Year-on-Year Investment Trends
Venrock has invested in 47 companies over the last 11 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 2 investments, while as of Jun 2026, it has made 1 investment in this year. Its most recent first time investment was in Maze Therapeutics and most recent follow-on round was in Lycia Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 2 | 0 | 2 |
2024 | 7 | 0 | 7 |
2023 | 4 | 1 | 5 |
2022 | 2 | 0 | 2 |
2021 | 5 | 1 | 6 |
2020 | 5 | 0 | 5 |
2019 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
Venrock's Investments by Stage
Venrock has made 12 investments in Post IPO stage with an average round size of $112M, 9 investments in Series B stage with an average round size of $105M and 5 investments in Series A stage with an average round size of $163M.Stage of entry | No. of Investments |
|---|---|
Post IPO | 12 |
Series B | 9 |
Series A | 5 |
Series C | 2 |
PE | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Venrock's Investments by Sector
Venrock has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Consumer and Enterprise Applications. Notably, it has invested in 43 Tech companies, 42 Enterprise (B2B) companies, 2 Consumer (B2C) companies and at least 2 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 28 |
High Tech | 5 |
Sustainability Tech | 4 |
Consumer | 1 |
Enterprise Applications | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Venrock's Investments by Geography
Venrock has made most investments in United States (23), followed by Canada where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 23 |
Canada | 2 |
Ireland | 2 |
China | 1 |
France | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Venrock's recent investments
Venrock has made 1 investments in 2026 so far - Lycia Therapeutics.Here are the most recent investments by Venrock:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 10, 2026 | United States | Series D | 3000 | ||
Sep 11, 2025 | United States | Post IPO | 4113 | ||
Jun 25, 2025 | United States | Post IPO | 7145 | ||
Oct 25, 2024 | Canada | Post IPO | 6399 | [+5] | |
2024 | United States | Seed | 8739 |
IPOs and Publicly Listed companies in Venrock's Portfolio
20 of Venrock's portfolio companies have become public. Lycia Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2026 at marketcap of $991M and Korsana got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Venrock's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 23, 2026 | Apr 26, 2024 | Series C | 9061 | |
Sep 09, 2026 | 2024 | Seed | 5850 | |
Jan 31, 2025 | Sep 11, 2025 | Post IPO | 2130 | |
Oct 11, 2024 | Jun 08, 2023 | Series B | 9094 | |
Nov 01, 2023 | Oct 25, 2024 | Post IPO | 2920 |
Acquired companies in Venrock's Portfolio
17 companies from Venrock's portfolio have been acquired. The most recent acquisition was Nuvalent in Jun 2026 by GSK for $*****.Here are Venrock's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 09, 2026 | May 11, 2021 | Series B | 6082 | |
May 03, 2026 | - | - | 5080 | |
Mar 31, 2026 | Feb 16, 2021 | Series A | 9600 | |
Jan 08, 2026 | - | - | 9394 | |
Dec 12, 2025 | - | - | 9909 |
Team profile of Venrock
Venrock has a team of 38 members including 16 Partners and 8 Principals located in United States. Venrock's team does not sit on the board of any company as of now.Here is a list of top team members in Venrock:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | ||
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | San Francisco | - | - | |
Partner | Palo Alto | - | ||
Partner | Palo Alto | - | - | |
Partner | Palo Alto | - | - | |
Partner | Menlo Park | - | ||
Partner | Menlo Park | - | - | |
Partner | Minneapolis | - | - | |
Partner | Palo Alto | - | - |
Co-investors of Venrock
Over the past 11 years, 246 investors have co-invested in Venrock's portfolio companies. This includes funds and angels.
- Invested before Venrock: Orbimed, Casdin Capital and 91 others have invested in rounds before Venrock. There are 5 companies where Orbimed has invested before Venrock and 4 companies where Casdin Capital has invested before Venrock.
- Top Co-investors of Venrock: 98 investors entered a company along with Venrock. These include investors like Boxer Capital (9 companies).
- Invested after Venrock: A total of 55 investors have invested in Venrock's portfolio after their investments. Top Investors include Venrock (6 companies), RTW Investments (5 companies) and TCG Crossover (4 companies).
Recent News related to Venrock
•
Timberlyne Therapeutics Raises $180M in Series A FundingFinSMEs•Jan 10, 2025•Timberlyne, Abingworth, Bain Capital Life Sciences, Venrock and 6 others
•
Sublingual psychedelic startup nets $60M for depression trialsFiercepharma•Nov 08, 2022•Lusaris Therapeutics, RA Capital Management, Venrock, Boxer Capital and 1 other
•
•
Annexon Announces $130 Million Private Placement FinancingGlobeNewswire•Jul 08, 2022•Annexon, Redmile Group, Adage Capital Management, Bain Capital Life Sciences and 6 others
•
Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B FinancingBusiness Wire•Dec 15, 2021•Mythic Therapeutics, Viking Global Investors, Venrock, Foresite Capital and 6 others
•
•
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for CancerPipelinereview•Jun 16, 2021•RayzeBio, Venrock, Perceptive Advisors, Vivo Capital and 13 others
•
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell TherapiesBusiness Wire•Feb 26, 2021•Artiva, Venrock, Acuta Capital Partners, EcoR1 and 12 others
•
Lianbio Leaps To $310mGlobal Corporate Venturing•Oct 30, 2020•LianBio, Pfizer, RA Capital Management, SDIC and 14 others
•
Kinnate Biopharma Closes $98 Million Series C FinancingBusiness Wire•Aug 26, 2020•Kinnate Biopharma, RA Capital Management, Viking Global Investors, Venrock and 13 others
